Comment from Peter Rosario
AnonymousOpposeIndividual
Summary: Dr. Peter Rosario, a medical professional, opposes the proposed changes to mifepristone's REMS and EASU oversight. He argues that the medication has more deleterious effects than previously reported and cites concerns regarding the underreporting of adverse effects and the ethical implications of chemical abortions.
Division of Dockets Management
U.S. Food and Drug Administration
Department of Health and Human Services
5630 Fishers Lane, Rm. 1061
Rockville, MD 20852
Re: FDA-2025-P-1576-0001; Citizen Petition “Citizen Petition from Attorney General of Massachusetts, et al.”
Dear FDA Representative,
I strongly oppose the requested changes to mifepristone’s REMS and EASU oversight. This medication has been recently found to have many more deleterious effects than previously reported.
Given the strong evidence demonstrating significant underreporting and biased presentation of
adverse effects related to chemical abortions, combined with severe ethical and societal concerns
inherent in current chemical abortion practices, I urge the FDA to reject the above-referenced petition.
Thank you for your considerations.
Peter Rosario MD